R. Di Liddo
F. Caroppo2
M. Kawasumi
B. Zavan- 1Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
- 2Dermatology Unit, Department of Medicine & Department of Women’s and Children’s Health, University of Padova, Padova, Italy
- 3Department of Dermatology, University of Washington School of Medicine, Seattle, WA, United States
- 4Department of Dermatology, The Ohio State University College of Medicine, Columbus, OH, United States
- 5The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States
- 6Department of Translational Medicine, University of Ferrara, Ferrara, Italy
Editorial on the Research Topic
Prevention and treatment of skin diseases
Over the past decade, significant progress has been made in the prevention and treatment of skin diseases, driven by therapeutic/technological advances, as well as an increased understanding of the pathophysiology of dermatological disorders. In this context, we compiled the scientific contributions of experts in this field to draw readers’ attention to the latest approaches in dermatology, emerging from both clinical and basic research. A total of 14 manuscripts is included in this Research Topic, covering the areas of wound healing, UVB damage, autoimmune/inflammatory diseases, benign skin tumors, and genetic disorders (Table 1).
Table 1. Scientific contributions to the Research Topic.
Skin wounds represent a significant global health Research Topic, as they can be a sign of an underlying disease and require specialized care to heal properly. When a reparative process rather than regeneration occurs, nonfunctional fibrotic tissue masses, namely scars, develop (Marshall et al., 2018). Currently, empirical treatments often rely on a one-size-fits-all approach, failing to consider individual patient characteristics. Thus, they have several limitations, such as 1) a lack of standardization and evidence; 2) ineffectiveness; and 3) practical restrictions. Notably, side effects and complications, i.e., skin atrophy following corticosteroid injection in hypertrophic scars, could be difficult to predict and can delay proper management, leading to suboptimal outcomes, patient dissatisfaction, and increased healthcare costs. In recent years, as reported in Contribution 1, network pharmacology and molecular docking (Sakuludomkan et al., 2025) have emerged as powerful tools in drug discovery and development, facilitating the identification of potential molecular targets and elucidation of drug-target interactions. Several advances have deepened our understanding of the molecular mechanisms underlying impaired wound healing (Holl et al., 2021). Unlike normal healing, diabetic wounds exhibit a weak initial inflammatory response followed by 1) a shift toward chronic inflammation; 2) a delayed and inadequate influx of inflammatory cells; 3) low levels of key cytokines like IL-6 and IL-8; and 4) an altered production of enzymes (i.e., neutral endopeptidases) or signaling molecules (i.e., VEGF, FGFs, NF-κB, NLRP3, Wnt/β-catenin and MAPK/ERK) (Patel et al., 2019). To improve the healing process, strategies have been developed to 1) suppress prolonged inflammation and promote the switch of M1 pro-inflammatory macrophages to the alternative, anti-inflammatory M2 phenotype (Cai et al., 2023), or 2) prevent chronic and excessive immune responses by modulating the initial wound phase (Cai et al., 2023; Zhao et al., 2024). Recent advances in technology have begun to enable personalized medicine in dermatology and to generate detailed molecular profiles for diagnosing and monitoring skin conditions (Sherrill et al., 2021). As discussed in Contribution 2, identifying transcriptomic characteristics in the early phase of skin wounds could be crucial for developing effective therapeutics (Park et al., 2022) and personalizing wound healing. Individualized medication is essential to achieving optimal patient outcomes at lower cost, but several Research Topic (e.g., genetic underrepresentation, integrating complex data, patient monitoring, and data privacy concerns) remain critical limitations to the development of new therapies. The precision medicine approach provides tools to classify patients with skin injuries into subclasses based on biomarkers that may predict responses to specific therapies. Additionally, this stratification may be used for patients undergoing elective surgery to provide personalized preventive measures and manage the risk of skin scarring. In personalized medicine, 3D biomaterials, such as nanofibers (Kamble et al., 2017), could also be used to create customized wound dressings and tissue-engineered skin grafts for targeted therapies (Cubo-Mateo and Gelinsky, 2021). This approach involves 3D bioprinting structures with specific properties, such as controlled drug release, antimicrobial activity, and enhanced cell growth, to match patients’ individual needs. By precisely layering biomaterials, including those with nanoscale features like nanotubes, researchers can engineer skin treatments that are more effective than traditional methods. As shown in Contributions 3 and 4, electrospun nanofibers and therapeutic agents, such as antimicrobials, growth factors, or anti-inflammatory drugs, can accelerate healing and reduce infection, although some limitations have been identified such as 1) weak mechanical strength and rapid degradation (mainly for natural polymers); 2) generation of acidic byproducts (especially with synthetic polymers); 3) high production costs; and 4) difficulties with large-scale manufacturing (Partovi et al., 2024). Given the inherent bioactivity and biocompatibility of natural polymers, as well as the favorable mechanical properties and tunable degradation profiles of synthetic polymers, combinations of these polymers are often used as temporary dressings for epidermal and dermal grafts and wounds. Nanofibers composed of polyvinyl alcohol (PVA)/polyethylene oxide (PEO)/chitosan (CS) are a promising strategy for wound healing due to their ability to create a moist environment, promote cell adhesion and tissue regeneration, and provide antibacterial properties (Alotaibi et al., 2024). PVA is a synthetic polymer used in biomedical applications due to its nontoxicity, hydrophilicity, and biocompatibility (Koosha et al., 2019). Widely used in electrospinning due to its optimal mechanical properties (Kamoun et al., 2021), it is blended with other polymers, such as chitosan (CS) (Alotaibi et al., 2024), to mimic the extracellular matrix and stimulate in vivo collagen production (Ribeiro et al., 2021). Another significant factor in skin damage is oxidative stress induced by ultraviolet B (UVB) rays, which are primarily responsible for skin photodamage (Schuch et al., 2017) and genotoxic effects (Cadet et al., 2015) via direct excitation of pyrimidine nucleobases and formation of cyclobutane pyrimidine dimers (CPDs), pyrimidine (6–4) pyrimidone (6-4 PPs). Therefore, protective measures, such as antioxidants, may help mitigate the harmful effects of UVB radiation. As reported in Contributions 5 and 6, through the coordinated stimulation of multiple signaling pathways, or the activation of homologous recombination repair (HRR), natural compounds, including anthraquinones (Lin et al., 2022) and derivatives of vitamins (i.e., retinoids) (Zasada and Budzisz, 2019) can enhance skin care efficacy against UVB-induced photodamage (Zeng et al., 2020), promoting 1) ROS scavenging; 2) dermal collagen balance; 3) inhibition of actinic keratosis; and 4) epidermal thickness restoration. Recently, the therapeutic use of monoclonal antibodies (mAbs) has increased significantly in dermatology. While beneficial, mAbs have been demonstrated to cause severe skin reactions, known as adverse dermatological events (ADEs). These reactions include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), erythema multiforme (EM), and fixed drug eruption (FDE) (Kherallah et al., 2025). In Generalized Pustular Psoriasis, the interleukin-36 receptor inhibitor Spesolimab-a humanized monoclonal antibody (Sehgal et al., 2011)- has demonstrated a higher incidence of lesion clearance than placebo, but also causes infections and systemic drug reactions (Bachelez et al., 2021). As reported in Contribution 8, when generalized pustular psoriasis coexists with acrodermatitis continua of Hallopeau, targeting the IL-36 proinflammatory cytokine with Spesolimab can result in a rapid and effective response, with minimal side effects. To determine the risks of Spesolimab, longer and larger trials are warranted in patients with pustular psoriasis (Bachelez et al., 2021). Particular attention must also be focused on establishing a comprehensive skin toxicity treatment and management program in patients treated with Sintilimab, a selective anti–PD-1 antibody, which is mainly used to treat cancers (i.e. Hodgkin lymphoma, non-small cell lung cancer, liver cancer, and metastatic colorectal cancer) and known to cause multiple cutaneous keratoacanthoma-like lesions predominantly manifesting as eczema-like maculopapular rashes, lichenoid reactions, vitiligo-like lesions, and flares of psoriasis (Yang et al., 2020). In Contribution 9, the authors report a patient case developing numerous eruptive keratoacanthoma-like lesions after the administration of Sintilimab for rectal adenocarcinoma with liver metastasis. Although eruptive keratoacanthoma-like lesions secondary to Sintilimab are exceptionally rarely reported, physicians should be aware of this cutaneous adverse effect as its use becomes more widespread. Skin lesions caused by mutations in the CYLD gene, which encodes a tumor suppressor that induces apoptosis, remain difficult to manage, as illustrated by the case report in Contribution 10. The search for safe, effective skincare products has boosted the popularity of natural products derived from plants, minerals, and animals, offering benefits such as moisturising, anti-ageing, anti-inflammatory, and soothing effects. However, with numerous skincare products claiming to contain natural ingredients, it is essential to critically evaluate the scientific evidence supporting their efficacy and benefits. Natural products, such as the Periplaneta Americana extract, have been demonstrated through integrated multi-omics analyses (transcriptomics, metabolomics, microbiome) to promote hair regeneration by activating Wnt signaling, suppressing inflammatory pathways, and restoring microbial balance (Contribution 11). However, further studies, including targeted inhibition of key signaling molecules, pathway-specific agonist/antagonist-mediated rescue assays, and in vivo validation using genetically modified models, are required to delineate the precise mechanisms through which natural products counteract alopecia areata and androgenetic alopecia, reducing inflammation and normalizing the skin’s microbiota. Although they are effective in treating non-scarring alopecia (Contributions 11, 12, 13), metabolic syndrome-associated psoriasis (Contribution 7), or pruritus (Contribution 14), the safety profiles and side effects of plant extracts warrant considerable attention, as they may vary and cause uncontrolled effects.
Author contributions
RD: Writing – review and editing, Writing – original draft. FC: Writing – review and editing. MK: Writing – review and editing. BZ: Writing – review and editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Almasi, L., Arkan, E., Farzaei, M. H., Iranpanah, A., Jalili, C., Abbaszadeh, F., et al. (2025). Preparation of Tragopogon graminifolius-loaded electrospun nanofibers and evaluating its wound healing activity in a rat model of skin scar. Front. Pharmacol. 16, 1533010. doi:10.3389/fphar.2025.1533010
Alotaibi, B. S., Khan, A. K., Kharaba, Z., Yasin, H., Yasmin, R., Ijaz, M., et al. (2024). Development of poly(vinyl alcohol)-chitosan composite nanofibers for dual drug therapy of wounds. ACS Omega 9, 12825–12834. doi:10.1021/acsomega.3c08856
Bachelez, H., Choon, S. E., Marrakchi, S., Burden, A. D., Tsai, T. F., Morita, A., et al. (2021). Trial of spesolimab for generalized pustular psoriasis. N. Engl. J. Med. 385, 2431–2440. doi:10.1056/NEJMoa2111563
Cadet, J., Douki, T., and Ravanat, J. L. (2015). Oxidatively generated damage to cellular DNA by UVB and UVA radiation. Photochem Photobiol. 91, 140–155. doi:10.1111/php.12368
Cai, Y., Chen, K., Liu, C., and Qu, X. (2023). Harnessing strategies for enhancing diabetic wound healing from the perspective of spatial inflammation patterns. Bioact. Mater 28, 243–254. doi:10.1016/j.bioactmat.2023.04.019
Cubo-Mateo, N., and Gelinsky, M. (2021). Wound and skin healing in space: the 3D bioprinting perspective. Front. Bioeng. Biotechnol. 9, 720217. doi:10.3389/fbioe.2021.720217
Guo, R. X., Zhao, Y. K., Hu, K. J., Jia, K. M., Shi, W., Yi, X. Y., et al. (2025). Research progress in the treatment of non-scarring alopecia: mechanism and treatment. Front. Pharmacol. 16 , 1544068. doi:10.3389/fphar.2025.1544068
Guan, T., Yang, X., Hong, C., Zhu, J., Xiao, P., Yang, Y., et al. (2025). Periplaneta americana extract (L.) promotes hair regrowth in Alopecia areata mice by reducing inflammation and modulating skin microbiota. Front. Pharmacol. 16, 1590648. doi:10.3389/fphar.2025.1590648
Gaydina, T. A., Patsap, O. I., and Buianova, A. A. (2024). Case report: Multiple facial trichoepitheliomas caused by p.Val835SerfsTer52 variant of CYLD gene. Front. Med. (Lausanne) 11, 1458723. doi:10.3389/fmed.2024.1458723
Holl, J., Kowalewski, C., Zimek, Z., Fiedor, P., Kaminski, A., Oldak, T., et al. (2021). Chronic diabetic wounds and their treatment with skin substitutes. Cells 10, 655. doi:10.3390/cells10030655
Jiang, L., Zeng, X., Li, H., and Wu, J. (2025). Network pharmacology and molecular docking analysis on molecular targets and mechanisms of scar healing ointment in the treatment of hypertrophic scars. Front. Pharmacol. 16, 1511570. doi:10.3389/fphar.2025.1511570
Kamble, P., Sadarani, B., Majumdar, A., and Bhullar, S. (2017). Nanofiber based drug delivery systems for skin: a promising therapeutic approach. J. Drug Deliv. Sci. Technol. 41, 124–133. doi:10.1016/j.jddst.2017.07.003
Kamoun, E. A., Loutfy, S. A., Hussein, Y., and Kenawy, E. S. (2021). Recent advances in PVA-polysaccharide based hydrogels and electrospun nanofibers in biomedical applications: a review. Int. J. Biol. Macromol. 187, 755–768. doi:10.1016/j.ijbiomac.2021.08.002
Kherallah, K., Ahmad, I., Bandara, A., Kattoula, J., Rodriguez, I., and Worswick, S. (2025). Adverse cutaneous reactions to monoclonal antibodies: Stevens-johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and fixed drug eruption - a systematic review. Biomed. Hub. 10, 105–115. doi:10.1159/000545623
Koosha, M., Raoufi, M., and Moravvej, H. (2019). One-pot reactive electrospinning of chitosan/PVA hydrogel nanofibers reinforced by halloysite nanotubes with enhanced fibroblast cell attachment for skin tissue regeneration. Colloids Surf. B Biointerfaces 179, 270–279. doi:10.1016/j.colsurfb.2019.03.054
Li, S., Ye, X., Li, X., Yang, Y., Zhang, Z., Cui, H., et al. (2025). Case Report: Multiple cutaneous keratoacanthoma-like lesions in a colorectal cancer patient treated with sintilimab. Front. Pharmacol. 16, 1535220. doi:10.3389/fimmu.2025.1535220
Lin, C.-F., Chuang, S.-Y., Huang, T.-H., Nguyen, T. M. H., Wang, P.-W., Alalaiwe, A., et al. (2022). A systematic comparison of the effect of topically applied anthraquinone aglycones to relieve psoriasiform lesion: the evaluation of percutaneous absorption and anti-inflammatory potency. Biomed. and Pharmacother. 145, 112482. doi:10.1016/j.biopha.2021.112482
Luo, G., Kong, X., Wang, F., Wang, Z., Zhang, Z., Cui, H., et al. (2025). Therapeutic effects and mechanisms of Fufang Longdan mixture on metabolic syndrome with psoriasis via miR-29a-5p/IGF-1R axis. Front. Pharmacol. 16, 1585369. doi:10.3389/fphar.2025.1585369
Marshall, C. D., Hu, M. S., Leavitt, T., Barnes, L. A., Lorenz, H. P., and Longaker, M. T. (2018). Cutaneous scarring: basic science, Current treatments, and future directions. Adv. Wound Care (New Rochelle) 7, 29–45. doi:10.1089/wound.2016.0696
Mohammadi, G., Safari, M., Karimi, M., Iranpanah, A., Farzaei, M. H., Fakhri, S., et al. (2024). Preparation and characterization of Pistacia atlantica oleo-gum-resin-loaded electrospun nanofibers and evaluating its wound healing activity in two rat models of skin scar and burn wound. Front. Pharmacol. 15, 1474981. doi:10.3389/fphar.2024.1474981
Park, S. M., Kim, A., Lee, H., Baek, S. J., Kim, N. S., Park, M., et al. (2022). Systematic transcriptome analysis reveals molecular mechanisms and indications of bupleuri radix. Front. Pharmacol. 13, 1010520. doi:10.3389/fphar.2022.1010520
Park, S., Park, H. W., Seo, D. B., Yoo, D. S., and Bae, S. (2024). In vitro hair growth-promoting effects of araliadiol via the p38/PPAR-γ signaling pathway in human hair follicle stem cells and dermal papilla cells. Front. Pharmacol. 15 , 1482898. doi:10.3389/fphar.2024.1482898
Partovi, A., Khedrinia, M., Arjmand, S., and Ranaei Siadat, S. O. (2024). Electrospun nanofibrous wound dressings with enhanced efficiency through carbon quantum dots and citrate incorporation. Sci. Rep. 14, 19256. doi:10.1038/s41598-024-70295-9
Patel, S., Srivastava, S., Singh, M. R., and Singh, D. (2019). Mechanistic insight into diabetic wounds: pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomed. and Pharmacother. 112, 108615. doi:10.1016/j.biopha.2019.108615
Ribeiro, A. S., Costa, S. M., Ferreira, D. P., Calhelha, R. C., Barros, L., Stojković, D., et al. (2021). Chitosan/nanocellulose electrospun fibers with enhanced antibacterial and antifungal activity for wound dressing applications. React. Funct. Polym. 159, 104808. doi:10.1016/j.reactfunctpolym.2020.104808
Sakuludomkan, C., Khowsathit, J., Thippraphan, P., Koonrungsesomboon, N., Takuathung, M. N., and Taychaworaditsakul, W. (2025). Network pharmacology and molecular docking-based approach to explore potential bioactive compounds from Kaempferia parviflora on chemokine signaling pathways in the treatment of psoriasis disease. Int. J. Mol. Sci. 26, 5243. doi:10.3390/ijms26115243
Schuch, A. P., Moreno, N. C., Schuch, N. J., Menck, C. F. M., and Garcia, C. C. M. (2017). Sunlight damage to cellular DNA: focus on oxidatively generated lesions. Free Radic. Biol. Med. 107, 110–124. doi:10.1016/j.freeradbiomed.2017.01.029
Sehgal, V. N., Verma, P., Sharma, S., Srivastava, G., Aggarwal, A. K., Rasool, F., et al. (2011). Acrodermatitis continua of hallopeau: evolution of treatment options. Int. J. Dermatol 50, 1195–1211. doi:10.1111/j.1365-4632.2011.04993.x
Shang, J., Liu, Z., Liang, M., Yin, Z., Yang, Z., Ye, X., et al. (2025). Identification of compounds to promote diabetic wound healing based on transcriptome signature. Front. Pharmacol. 16, 1576056. doi:10.3389/fphar.2025.1576056
Sherrill, J. D., Finlay, D., Binder, R. L., Robinson, M. K., Wei, X., Tiesman, J. P., et al. (2021). Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment. PLoS One 16, e0260095. doi:10.1371/journal.pone.0260095
Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., et al. (2020). Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J. Thorac. Oncol. 15, 1636–1646. doi:10.1016/j.jtho.2020.07.014
Zasada, M., and Budzisz, E. (2019). Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Postepy Dermatol Alergol. 36, 392–397. doi:10.5114/ada.2019.87443
Zeng, H.-j., Sun, D.-q., Chu, S.-h., Zhang, J.-j., Hu, G.-z., and Yang, R. (2020). Inhibitory effects of four anthraquinones on tyrosinase activity: insight from spectroscopic analysis and molecular docking. Int. J. Biol. Macromol. 160, 153–163. doi:10.1016/j.ijbiomac.2020.05.193
Zhao, L., Li, J., Xu, X., Zhang, N., He, T., Yuan, Y., et al. (2024). A nature-based solution for regulating the inflammatory phase of diabetic wound healing using a cold atmospheric plasma. Cell Rep. Phys. Sci. 5, 102147. doi:10.1016/j.xcrp.2024.102147
Zheng, J., Ding, Y., Shi, Y., and Yi, X. (2025). Case report: successful treatment with spesolimab of acrodermatitis continua of Hallopeau in an older patient without IL36RN mutations. Front. Pharmacol. 15, 1440102. doi:10.3389/fimmu.2024.1440102
Keywords: skin disease, biologics, enzymes, precision medicine, immunotherapy
Citation: Di Liddo R, Caroppo F, Kawasumi M and Zavan B (2026) Editorial: Prevention and treatment of skin diseases. Front. Pharmacol. 16:1753830. doi: 10.3389/fphar.2025.1753830
Received: 25 November 2025; Accepted: 08 December 2025;
Published: 08 January 2026.
Edited and reviewed by:
Heike Wulff, University of California, Davis, United StatesCopyright © 2026 Di Liddo, Caroppo, Kawasumi and Zavan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: R. Di Liddo, cm9zYS5kaWxpZGRvQHVuaXBkLml0